The Master Regulator

Homeostasis is not a vague, mystical force; it is a real-time computation executed across billions of cellular nodes. Cell membranes are the distributed hardware, fatty acids are the raw bandwidth, and enzymes like NAPE-PLD are the localized execution scripts. When you starve the machine of its inputs, the network defaults, the uptime drops, and the system crashes into the exact state of cellular 'winter' described by Ovid.

The Endocannabinoid System was not formally discovered until 1988 — over fifty years after Cannabis was removed from the food chain. By the time science had the tools to characterize the system that Cannabis was feeding, the food had already been gone for two generations.

The ECS is not a system in the conventional sense — a discrete organ, a specific pathway, a localized network. It is woven through virtually every tissue in the body. It operates in the brain, the gut, the immune system, the reproductive system, the skin, the bones, the cardiovascular system, and the endocrine system simultaneously. Its two primary receptor types — CB1 and CB2 — are expressed throughout the body, with CB1 dominant in the nervous system and CB2 dominant in immune tissues, though both appear in most organ systems.

The system's primary role is homeostasis: maintaining internal balance in the face of constant external and internal disruption. When something in the body moves too far from its set point — too much inflammation, too little, too much pain signal, disrupted sleep architecture, immune overactivation — the ECS is one of the first systems recruited to bring it back. It functions, in this sense, as the body's buffer against extremes.

What the ECS Signals With

The ECS's primary signaling molecules — anandamide and 2-arachidonoylglycerol (2-AG) — are not stored and released like most neurotransmitters. They are manufactured on demand, at the moment the signal is needed, from fatty acid precursors embedded in cell membranes. The cell identifies that a signal is required, cleaves the appropriate precursor from the membrane using specialized enzymes, and releases the resulting endocannabinoid to bind with a nearby receptor.

This is Piomelli's central finding in practice: the ECS runs on membrane lipids as raw material, and on enzymatic machinery to convert those lipids into signals. The quality and availability of both — the fatty acid composition of cell membranes, and the cofactors that the enzymes require — determine whether the ECS can respond at all, and how well. A membrane built from the wrong fatty acid ratios, or an enzyme unable to function for want of a mineral cofactor, means a signal that cannot be generated, or one that is immediately degraded before it can reach its receptor.

This is the molecular basis of ECS deficiency. It is not that the system is absent. It is that it cannot manufacture what it needs, because the raw materials are not there.

Breadcrumbs: Piomelli (2003) Nature Reviews Neuroscience 4(11):873; Devane et al. (1992) Science 258(5090):1946

The Acidic Vitamers: The ECS's Vitamins

When you consume raw Cannabis leaf and flower, you are not consuming THC or CBD. You are consuming their acidic precursors — THCA, CBDA, and CBGA — in a form that your body processes very differently from the heated versions.

At body temperature and at the pH of the stomach, these compounds are not meaningfully converted to their decarboxylated (psychoactive) forms — decarboxylation is driven by heat, not acid, and the activation energy it requires is not met at physiological temperature, so the conversion is negligible. The vast majority circulate through the body largely intact as the acidic forms — ionized at blood pH, structurally stable, and biologically active in ways that are distinct from and complementary to the endocannabinoids the body makes itself.

The Floyd-Benjamin research advances the hypothesis that these acidic forms function as ECS vitamers: conditional micronutrients for the ECS, analogous to the way beta-carotene functions as a vitamer for Vitamin A, or the way the multiple forms of tocopherol and tocotrienol together constitute the Vitamin E family. The structural parallels are not merely metaphorical. These compounds are lipophilic. They accumulate in adipose tissue in patterns that resemble fat-soluble vitamins. They undergo metabolic activation through processes analogous to the hydroxylation sequences that convert provitamin D into its active form. What they do not yet have is a characterized deficiency phenotype — the single criterion, of eight formal tests for vitamin status, that this compound class has not yet met. Age-related ECS signaling change is real and documented, but it isn't a simple decline: some signals drop with age in some tissues and not others, and in at least one large cohort, higher levels of some of these signaling compounds tracked with worse — not better — cognitive outcomes in older women. That complexity is why the working model here is a set-point the body is trying to maintain, not a tank that simply runs low with age and refills with supplementation, and it's exactly what a formal deficiency phenotype would need to account for.

The strongest evidence for this comes from THCA specifically, and it answers a question the earlier research could only gesture at: what, mechanically, makes the acidic form biologically active in its own right? THCA binds the nuclear receptor PPAR-gamma — the same receptor class vitamin A’s active form uses to regulate gene transcription — and it does so through its carboxylate group specifically, the very structural feature decarboxylation removes. This is not a Cannabis-only curiosity: the identical binding mode has been found in amorfrutins, unrelated compounds from edible legumes such as licorice root, acting at the same site on the same receptor. And THCA acts there as a partial, selective modulator rather than a full agonist — the same receptor class targeted by the diabetes drug rosiglitazone, but without rosiglitazone’s associated weight gain and bone loss. Decarboxylation does not merely change the molecule’s psychoactivity. It removes the one structural feature that makes this particular mechanism possible at all.

The formal hypothesis requires clinical validation. What the existing evidence already supports is that consuming raw Cannabis leaf and flower provides the ECS with a family of compounds it cannot make endogenously, that interact with its signaling network in ways that dietary fatty acids alone cannot replicate, and that are entirely absent from every modern dietary pattern.

Breadcrumbs: Benjamin & Floyd (2026) zenodo.24061187 (ECS Vitamers); Floyd (2025) zenodo.21756221 (Stomach Acid)

What Happens When It Gets Fed

The hypothesis this research proposes is that when an ECS that has been operating below its functional set-point finally receives the inputs it requires, the response would not be subtle.

Inflammation that had become chronic would be expected to resolve. Pain signals that had been amplified beyond their original cause would be expected to return to appropriate levels. Sleep architecture would be expected to normalize — the ECS governs the cycling of the brain's sleep phases through the melatonin-CB1 signaling axis, and when that axis is properly supported, sleep would become genuinely restorative rather than merely time spent unconscious. Mood would be expected to stabilize. Appetite would be expected to self-regulate. The immune system would be expected to stop generating inflammatory responses that have no clear target. The model behind this isn't a simple “more signal, more benefit” story — these compounds appear to act as normalizers pulling tone toward a set-point rather than pushing it in one direction, so the predicted benefit is for a system starting below that point, not a universal push upward regardless of where someone starts.

If this holds, none of these would be drug effects. They would be the effects of a system functioning at the level it was designed to function, because it finally has what it needs. The distinction matters, because it means the goal is not to consume cannabis forever in escalating doses. That would be symptom management – a downstream solution. The goal, if the hypothesis is confirmed, is to feed the ECS until it reaches a stable, sustained nutritional sufficiency — and then maintain that sufficiency the same way you maintain any other aspect of nutritional health. Doing so would provide an upstream fix. A nutritional remedy. A recipe, not a drug.